☆ 4.2 Review

Updates in Risk Stratification in Myelodysplastic Syndromes

CANCER JOURNAL (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Hematology

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal

Elihu Estey et al.

Summary: Including patients with 10% to 30% blasts (AML/MDS) in both AML and MDS studies would allow for testing the independent effect of blast percentage on outcome, provide more treatment options for patients, and potentially simplify the regulatory approval process.

BLOOD (2022)

添加到收藏夹

Article Hematology

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber et al.

Summary: In 2016, the WHO, Society for Hematopathology, and European Association for Haematopathology collaborated to update the classification of myeloid neoplasms and acute leukemias, advancing the field of myeloid neoplasms and acute leukemias.

BLOOD (2022)

添加到收藏夹

Review Oncology

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

Joseph D. Khoury et al.

Summary: This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms, emphasizing the refinement of diagnostic criteria and the importance of actionable biomarkers, while maintaining global applicability.

LEUKEMIA (2022)

添加到收藏夹

Meeting Abstract Hematology

Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Hypoplastic Myelodysplastic Syndromes

Luis E. Aguirre et al.

BLOOD (2022)

添加到收藏夹

Meeting Abstract Hematology

Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in TherapyRelated Myelodysplastic Syndromes

Luis E. Aguirre et al.

BLOOD (2022)

添加到收藏夹

Meeting Abstract Hematology

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Elisabetta Sauta et al.

BLOOD (2022)

添加到收藏夹

Meeting Abstract Hematology

Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes

Luis E. Aguirre et al.

BLOOD (2022)

添加到收藏夹

Article Oncology

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS

A. Kuendgen et al.

Summary: The study shows that therapy-related myelodysplastic syndromes (t-MDS) are as heterogeneous as primary MDS, and require the same careful differentiation regarding risk. Despite less favorable clinical outcomes in t-MDS subsets compared to primary MDS, classification and prognostic scoring effectively separated t-MDS patients into different risk groups.

LEUKEMIA (2021)

添加到收藏夹

Article Hematology

It is time to shift the treatment paradigm in myelodysplastic syndromes: A focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDS

Luis E. Aguirre et al.

Summary: Therapeutic options for higher risk myelodysplastic syndromes have been limited, but recent developments in DNA sequencing have led to targeted drug development. Strategies such as disrupting protein ubiquitination, modulating macrophage activity, and blocking immune checkpoints show promise in improving treatment outcomes for high-risk MDS.

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2021)

添加到收藏夹

Article Oncology

Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes

Aziz Nazha et al.

Summary: This study developed a personalized prediction model for MDS patients using machine learning techniques and incorporating clinical and genomic data, which showed superior performance in predicting survival and leukemia transformation probabilities compared to established models. The model was validated in external cohorts, demonstrating its potential for dynamic and accurate prognostic predictions at different time points in a patient's disease course.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome?

Bruno Fattizzo et al.

Summary: Hypoplastic myelodysplastic syndromes (hMDS) pose a diagnostic challenge, blending features of both MDS (dysplasia, genetic lesions, cytopenias) and aplastic anemia (low cellularity, autoimmunity). There are two potential hMDS phenotypes: one proinflammatory and autoimmune, resembling AA and responding to immunosuppression; the other MDS-like, dominated by genetic lesions and prone to leukemic evolution. Personalized treatment and monitoring based on the predominant hMDS phenotype may be beneficial for patient management.

CANCERS (2021)

添加到收藏夹

Article Oncology

Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes

Matteo Bersanelli et al.

Summary: The study identified eight distinct subgroups of MDS based on specific genomic features, each with different prognostic outcomes. By integrating clinical and genomic variables, a novel prognostic model was developed to provide personalized survival predictions for MDS patients. This model significantly improved the accuracy of current prognostic tools and has the potential to revolutionize disease classification and prognosis in the future.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Pierre Fenaux et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Hematology

Genetics of MDS

Seishi Ogawa

BLOOD (2019)

添加到收藏夹

Article Oncology

Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome

Elisa Bono et al.

LEUKEMIA (2019)

添加到收藏夹

Review Oncology

Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome

James A. Kennedy et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation

R. C. Lindsley et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Review Oncology

Therapy-related myeloid neoplasms: when genetics and environment collide

Megan E. McNerney et al.

NATURE REVIEWS CANCER (2017)

添加到收藏夹

Article Hematology

Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation

Tetsuichi Yoshizato et al.

BLOOD (2017)

添加到收藏夹

Article Oncology

Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation

Matteo G. Della Porta et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation

Rafael Bejar et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

添加到收藏夹

Article Hematology

Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes

Asmita Mishra et al.

AMERICAN JOURNAL OF HEMATOLOGY (2013)

添加到收藏夹

Article Hematology

The genetic basis of myelodysplasia and its clinical relevance

Mario Cazzola et al.

BLOOD (2013)

添加到收藏夹

Article Hematology

Clinical and biological implications of driver mutations in myelodysplastic syndromes

Elli Papaemmanuil et al.

BLOOD (2013)

添加到收藏夹

Review Oncology

An evolutionary perspective on chronic myelomonocytic leukemia

R. Itzykson et al.

LEUKEMIA (2013)

添加到收藏夹

Article Hematology

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Peter L. Greenberg et al.

BLOOD (2012)

添加到收藏夹

Article Oncology

Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome

Rami S. Komrokji et al.

CANCER (2012)

添加到收藏夹

Article Hematology

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

Sabine Kayser et al.

BLOOD (2011)

添加到收藏夹

Article Medicine, General & Internal

Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts

E. Papaemmanuil et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

添加到收藏夹

Article Oncology

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

Hagop Kantarjian et al.

CANCER (2008)

添加到收藏夹

Article Oncology

A prognostic score for patients with lower risk myelodysplastic syndrome

G. Garcia-Manero et al.

LEUKEMIA (2008)

添加到收藏夹

Article Oncology

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes

Luca Malcovati et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.